Jing Meng

Jing Meng

Auto-generated profile, based on publicly available information

Jing Meng

State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JTjingzhuo tian
jingzhuo tian
CLChenyue Liu
Chenyue Liu
LWLianmei Wang
Lianmei Wang
ZXZhong Xian
Zhong Xian
YZYong Zhao
Yong Zhao
ALAi-hua Liang
Ai-hua Liang

26 December 2013 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
YGYin Guan
Yin Guan
HZHong Zhao
Hong Zhao
JMJing Meng
Jing Meng
XYXiang Yan
Xiang Yan
SJShunchang Jiao
Shunchang Jiao

27 September 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
MJMeng Jing
Meng Jing
XHXia He
Xia He
CCCheng Zhi Cai
Cheng Zhi Cai
QMQi Zhi Ma
Qi Zhi Ma
KLKai Li
Kai Li
YWYongsheng Wang
Yongsheng Wang
Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) is clinically and genetically heterogeneous, with concurrent RB1/TP53 mutations, indicating an increased risk of transformation into small cell lung cancer (SCLC). When tumor cells convert into a different histological subtype, they lose their dependence on the original oncogenic driver, resulting in therapeutic resistance. However, the molecular details associated with this transformation remain unclear. It has been difficult to define molecular mechanisms of neuroendocrine (NE) transformation in lung cancer due to a lack of pre- and post-transformation clinical samples. In this study, we established a NSCLC cell line with concurrent RB1/TP53 mutations and built corresponding patient-derived xenograft (PDX) models to investigate the mechanisms underlying transformation to SCLC. Studying these PDX models, we demonstrate that EGFR loss facilitates lineage plasticity of lung adenocarcinoma initiated by biallelic mutations of TP53 and RB1. Gene expression analysis of these EGFR knockout tumors revealed altered expression of neuroendocrine synapse-associated lineage genes. There is an increased expression of epigenetic reprogramming factors like Sox2 and gene associated with neural development like NTRK in these EGFR knockout tumors. These findings uncovered the role of EGFR in the acquisition of plasticity, which is the ability of a cell to substantially modify its identity and take on a new phenotype, and defined a novel landscape of potential drivers of NE transformation in lung cancer.